Results of a study presented today at the at the International Liver CongressTM 2010 reveals the effects of a new drug for the treatment of primary biliary cirrhosis, and shows further evaluation is necessary.
INT-747 is a novel derivative of a human bile acid CDCA (that binds to the farnesoid-X receptor). In patients with PBC, addition of INT-747 to UDCA resulted in a significant amelioration of liver enzymes compared to placebo.
PBC is a chronic disease that damages bile ducts. Bile can no longer flow and builds up in the liver instead, damaging the liver cells and causing inflammation and scarring. This eventually leads to cirrhosis.
If our reporting has informed or inspired you, please consider making a donation. Every contribution, no matter the size, empowers us to continue delivering accurate, engaging, and trustworthy science and medical news. Independent journalism requires time, effort, and resources—your support ensures we can keep uncovering the stories that matter most to you.
Join us in making knowledge accessible and impactful. Thank you for standing with us!